B. Chanu

3.6k total citations
31 papers, 327 citations indexed

About

B. Chanu is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, B. Chanu has authored 31 papers receiving a total of 327 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Surgery, 9 papers in Cardiology and Cardiovascular Medicine and 5 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in B. Chanu's work include Lipoproteins and Cardiovascular Health (11 papers), Lipid metabolism and disorders (6 papers) and Cancer, Lipids, and Metabolism (5 papers). B. Chanu is often cited by papers focused on Lipoproteins and Cardiovascular Health (11 papers), Lipid metabolism and disorders (6 papers) and Cancer, Lipids, and Metabolism (5 papers). B. Chanu collaborates with scholars based in France, Italy and Greece. B. Chanu's co-authors include Emmanuel Cosson, Paul Valensi, J Rouffy, Minh Tuan Nguyen, A. Avignon, Ariane Sultan, A. Facchini, Fosca Quarti Trevano, Guıdo Grassı and Giuseppe Mancia and has published in prestigious journals such as SHILAP Revista de lepidopterología, Diabetes Care and European Heart Journal.

In The Last Decade

B. Chanu

29 papers receiving 303 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
B. Chanu France 10 123 117 111 51 42 31 327
A. S. Krolewski United States 7 163 1.3× 120 1.0× 332 3.0× 102 2.0× 26 0.6× 14 507
V Schliack Germany 8 116 0.9× 118 1.0× 313 2.8× 77 1.5× 29 0.7× 18 470
Stephen Davies United Kingdom 5 51 0.4× 100 0.9× 108 1.0× 82 1.6× 8 0.2× 8 328
H. Zeller Germany 4 197 1.6× 112 1.0× 299 2.7× 39 0.8× 21 0.5× 6 488
M. Enderle Germany 8 57 0.5× 241 2.1× 94 0.8× 39 0.8× 36 0.9× 10 469
Ch. Schnack Austria 14 53 0.4× 200 1.7× 154 1.4× 85 1.7× 14 0.3× 20 500
A Czyźyk Poland 9 170 1.4× 151 1.3× 377 3.4× 139 2.7× 23 0.5× 19 600
Seishi Nagano Japan 10 80 0.7× 96 0.8× 112 1.0× 63 1.2× 16 0.4× 21 327
A. Tselepis Greece 13 166 1.3× 100 0.9× 132 1.2× 80 1.6× 9 0.2× 23 539
Annette Krämer‐Guth Germany 12 167 1.4× 46 0.4× 109 1.0× 38 0.7× 8 0.2× 20 330

Countries citing papers authored by B. Chanu

Since Specialization
Citations

This map shows the geographic impact of B. Chanu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Chanu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Chanu more than expected).

Fields of papers citing papers by B. Chanu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Chanu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Chanu. The network helps show where B. Chanu may publish in the future.

Co-authorship network of co-authors of B. Chanu

This figure shows the co-authorship network connecting the top 25 collaborators of B. Chanu. A scholar is included among the top collaborators of B. Chanu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Chanu. B. Chanu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Valensi, Paul, A. Avignon, Ariane Sultan, et al.. (2016). Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: a cross-sectional study. Cardiovascular Diabetology. 15(1). 104–104. 56 indexed citations
2.
Cosson, Emmanuel, et al.. (2012). The report of male gender and retinopathy status improves the current consensus guidelines for the screening of myocardial ischemia in asymptomatic type 2 diabetic patients. Nutrition Metabolism and Cardiovascular Diseases. 23(6). 557–565. 11 indexed citations
3.
Cosson, Emmanuel, et al.. (2011). Cardiovascular Risk Prediction Is Improved by Adding Asymptomatic Coronary Status to Routine Risk Assessment in Type 2 Diabetic Patients. Diabetes Care. 34(9). 2101–2107. 31 indexed citations
4.
Querques, Giuseppe, et al.. (2010). DHA supplementation for late onset Stargardt disease: NAT-3 study. SHILAP Revista de lepidopterología. 1 indexed citations
5.
Valensi, Paul, B. Chanu, & Emmanuel Cosson. (2006). Obesity, Metabolic Syndrome, Diabetes and Arterial Hypertension. Immunology Endocrine & Metabolic Agents - Medicinal Chemistry. 6(4). 407–423. 7 indexed citations
6.
Chanu, B. & P. Valensi. (2005). Les désordres lipidiques des patients atteints d’affections causées par le VIH. La Presse Médicale. 34(15). 1087–1094. 7 indexed citations
7.
Benlian, Pascale, et al.. (2003). NAT1: A Feasibility Study of Oral DHA Supplementation as a Nutritional AMD Treatment. Investigative Ophthalmology & Visual Science. 44(13). 4994–4994. 3 indexed citations
8.
9.
Saint-Jore, Bruno, Mathilde Varret, Christiane Dachet, et al.. (2000). Autosomal dominant type IIa hypercholesterolemia: evaluation of the respective contributions of LDLR and APOB gene defects as well as a third major group of defects. European Journal of Human Genetics. 8(8). 621–630. 10 indexed citations
10.
Lefèvre, Guillaume, et al.. (1996). Determination of Plasma Protein-Bound Malondialdehyde by Derivative Spectrophotometry. Clinical Chemistry and Laboratory Medicine (CCLM). 34(8). 631–636. 12 indexed citations
11.
Chanu, B., et al.. (1995). [Acute rhabdomyolysis associated with digestive disorders during a voluntary overdose of ciprofibrate].. PubMed. 19(2). 231–2. 1 indexed citations
12.
Emmerich, Joseph, Isabelle Aubert, B. Bauduceau, et al.. (1990). Efficacy and safety of simvastatin (alone or in association with cholestyramine). A 1-year study in 66 patients with type II hyperlipoproteinaemia. European Heart Journal. 11(2). 149–155. 12 indexed citations
13.
14.
Aubert, Isabelle, Joseph Emmerich, B. Chanu, et al.. (1988). [Effects of simvastatin on plasma lipids, lipoproteins and apoproteins (A1 and B). 24 cases of major primary hypercholesterolemia].. PubMed. 17(18). 901–4. 7 indexed citations
15.
Aubert, Isabelle, et al.. (1988). [Removal of low density lipoproteins on dextrans sulfate in 2 patients with familial monogenic hypercholesterolemia].. PubMed. 139 Suppl 1. 72–6. 1 indexed citations
16.
Rouffy, J, et al.. (1985). Effects of Labetalol (400 mg/day) on Plasma Lipids, Lipoproteins and Apolipoproteins in Hypertensive Patients. Journal of Hypertension. 3(5). 545–545. 2 indexed citations
17.
Rouffy, J, et al.. (1985). Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B. Atherosclerosis. 54(3). 273–281. 22 indexed citations
18.
Rouffy, J, et al.. (1983). [Lipids, lipoproteins, apoproteins and clinical arteriopathic manifestations].. PubMed. 31(4). 261–70. 1 indexed citations
19.
Chanu, B., et al.. (1983). [Primary hyperlipoproteinemias. Clinical, biological and physiopathological aspects].. PubMed. 59(41). 2861–71. 1 indexed citations
20.
Chanu, B., et al.. (1982). PSEUDO HYPERTRIGLYCERIDEMIE DUE A UNE HYPERGLYCEROLEMIE PAR DEFICIT EN GLYCEROL-KINASE. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A. S. Krolewski Breakdown of academic impact, for papers by V Schliack Breakdown of academic impact, for papers by Stephen Davies Breakdown of academic impact, for papers by H. Zeller Breakdown of academic impact, for papers by M. Enderle Breakdown of academic impact, for papers by Ch. Schnack Breakdown of academic impact, for papers by A Czyźyk Breakdown of academic impact, for papers by Seishi Nagano Breakdown of academic impact, for papers by A. Tselepis Breakdown of academic impact, for papers by Annette Krämer‐Guth
Rankless by CCL
2026